Evidence map›Paper›PMID 41032077›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [

Christos Sachpekidis, Marina Hajiyianni, Martin Grözinger, Maja Piller, Annette Kopp-Schneider, Elias K Mai, Lukas John, Sandra Sauer, Niels Weinhold, Ekaterina Menis and 11 more

Abstract readClinical Trial, Phase IIIRandomized Controlled TrialValidation Study
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Interpreting [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Christos SachpekidisClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany. c.sachpekidis@dkfz-heidelberg.de.ORCID 0000-0001-8739-8741
Marina HajiyianniHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Martin GrözingerDivision of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maja PillerClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.
Annette Kopp-SchneiderDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Elias K MaiHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Lukas JohnHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Sandra SauerHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Niels WeinholdHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Ekaterina MenisHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Olof EnqvistEigenvision AB, Malmö, Sweden.
Marc S RaabHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Anna JauchInstitute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Lars EdenbrandtDepartment of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
Michael HundemerHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Alexander BrobeilInstitute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Johann JendeDivision of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heinz-Peter SchlemmerDivision of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stefan DelormeDivision of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hartmut GoldschmidtInternal Medicine V, Hematology, Oncology and Rheumatology, GMMG Study Group, Heidelberg University Hospital and National Center for Tumor Diseases, Heidelberg, Germany.
Antonia Dimitrakopoulou-StraussClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe clinical significance of medullary abnormalities in the appendicular skeleton detected by computed tomography (CT) in patients with multiple myeloma (MM) remains incompletely elucidated. This study aims to validate novel low-dose CT-based methods for quantifying myeloma bone marrow (BM) volume in the appendicular skeleton of MM patients undergoing [ MATERIALS AND

methodsSeventy-two newly diagnosed, transplantation eligible MM patients enrolled in the randomised phase 3 GMMG-HD7 trial underwent whole-body [

resultsAt baseline, the median CTv (manual) was 26.1 Hounsfield units (HU) and the median cCTv (semi-automated) was 5.5 HU. Both CT-based methods showed weak but significant correlations with disease burden indicators: CTv correlated with BM plasma cell infiltration (r = 0.29; p = 0.02) and β2-microglobulin levels (r = 0.28; p = 0.02), while cCTv correlated with BM plasma cell infiltration (r = 0.25; p = 0.04). Appendicular CT values further demonstrated significant associations with PET-derived parameters. Notably, SUVmax values from the BM of long bones were strongly correlated with both CTv (r = 0.61; p < 0.001) and moderately with cCTv (r = 0.45; p < 0.001). Patients classified as having increased [

conclusionsNovel CT-based quantification approaches for assessing BM involvement in the appendicular skeleton correlate with key clinical and PET parameters in MM. As low-dose, standardized techniques, they show promise for inclusion in MM imaging protocols, potentially enhancing assessment of disease extent and treatment response.

Indexed as

Bone MarrowFluorodeoxyglucose F18Multiple MyelomaPositron Emission Tomography Computed TomographyRadiation DosageAdultAgedFemaleHumansMaleMiddle AgedRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals[18F]FDG PET/CTArtificial intelligenceInduction therapyIsatuximabItalian Myeloma criteria for PET Use (IMPeTUs)Minimal residual disease (MRD)Multiple myelomaWhole-body low-dose CT

Identifiers

PMID41032077
PMCPMC12860749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.